Abstract:Stroke is a leading cause of mortality and morbidity with a paucity of effective pharmacological treatments. We have previously identified insulin-regulated aminopeptidase (IRAP) as a potential target for the development of a new class of drugs for the treatment of stroke, as global deletion of this gene in mice significantly protected against ischemic damage. In the current study, we demonstrate that small molecular weight IRAP inhibitors reduce infarct volume and improve neurological outcome in a hypertensive animal model of ischemic stroke. The effects of two structurally distinct IRAP inhibitors (HFI419 or SJM164) were investigated in a model of stroke where the middle cerebral artery was transiently occluded with endothelin-1 in the conscious spontaneously hypertensive rat. IRAP inhibitor was administered into the lateral ventricle at 2 or 6 h after stroke, with subsequent doses delivered at 24, 48 and 70 h post-stroke. Functional outcomes were assessed prior to drug treatment, and on day 1 and 3 post-stroke. Histological analyses and neuroinflammatory cytokine profiling were conducted at 72 and 24 h post-stroke respectively. IRAP inhibitor treatment following stroke significantly reduced infarct volume and improved neurological and motor deficits. These protective effects were maintained even when the therapeutic window was extended to 6 h. Examination of the cellular architecture at 72 h post-stroke demonstrated that IRAP expression was upregulated in CD11b positive cells and activated astrocytes. Furthermore, IRAP inhibitor treatment significantly increased gene expression for interleukin 6 and C–C motif chemokine ligand 2 in the ischemic core. This study provides proof-of-principle that selective inhibition of IRAP activity with two structurally distinct IRAP inhibitors reduces infarct volume and improves functional outcome even when the first dose is administered 6 h post-stroke. This is the first direct evidence that IRAP inhibitors are a class of drug with potential use in the treatment of ischemic stroke.

Potent neuroprotection after stroke afforded by a double-knot spider-venom peptide that inhibits acid-sensing ion channel 1a

Highly Effective Stroke Therapy Enabled by Genetically Engineered Viral Nanofibers

Network-Based Approach to Identify Potential Targets and Drugs That Promote Neuroprotection and Neurorepair in Acute Ischemic Stroke

Toxin-derived peptides: An unconventional approach to alleviating cerebral stroke burden and neurobehavioral impairments

Wasp Venom from Vespa Magnifica Acts As a Neuroprotective Agent to Alleviate Neuronal Damage after Stroke in Rats

Peptide OM-LV20 protects astrocytes against oxidative stress via the ‘PAC1R/JNK/TPH1’ axis

Pituitary Adenylate Cyclase-Activating Polypeptide: A Promising Neuroprotective Peptide in Stroke

Novel scorpion venom peptide HsTx2 ameliorates cerebral ischemic brain injury in rats via the MAPK signaling pathway

Vespakinin-M, a natural peptide from Vespa magnifica, promotes functional recovery in stroke mice

Combination Treatment With N-Acetyl-Seryl-Aspartyl-Lysyl-Proline and Tissue Plasminogen Activator Provides Potent Neuroprotection in Rats After Stroke

The Therapeutic Effects of SP-8356, a Verbenone Derivative, with Multimodal Cytoprotective Mechanisms in an Ischemic Stroke Rat Model

Pharmacological Validation of ASIC1a as a Druggable Target for Neuroprotection in Cerebral Ischemia Using an Intravenously Available Small Molecule Inhibitor

Unraveling neuroprotection with Kv1.3 potassium channel blockade by a scorpion venom peptide

Discovery of neuroprotective Agents: Potent, brain Penetrating, lipoic acid derivatives for the potential treatment of ischemic stroke by regulating oxidative stress and inflammation - a Preliminary study

Inhibition of CSPG receptor PTPσ promotes migration of newly born neuroblasts, axonal sprouting, and recovery from stroke

TAT-W61 Peptide Attenuates Neuronal Injury Through Blocking the Binding of S100b to the V-domain of Rage During Ischemic Stroke.

Neuroserpin and Extracellular Vesicles in Ischemic Stroke: Partners in Neuroprotection?

Ph-Sensitive, Cerebral Vasculature-Targeting Hydroxyethyl Starch Functionalized Nanoparticles For Improved Angiogenesis And Neurological Function Recovery In Ischemic Stroke

Thrombin-Responsive, Brain-Targeting Nanoparticles for Improved Stroke Therapy.

Chikusetsu Saponin IVa liposomes modified with a retro-enantio peptide penetrating the blood-brain barrier to suppress pyroptosis in acute ischemic stroke rats

Inhibition of insulin-regulated aminopeptidase confers neuroprotection in a conscious model of ischemic stroke